ABSTRACT
A high prevalence of low bone mineralization is documented in adult patients with cystic fibrosis (CF). Osteopenia is present in as much as 85% of adult patients and osteoporosis in 13 to 57% of them. In children, studies are discordant probably because of different control database. Denutrition, inflammation, vitamin D and vitamin K deficiency, altered sex hormone production, glucocorticoid therapy, and physical inactivity are well known risk factors for poor bone health. Puberty is a critical period and requires a careful follow-up for an optimal bone peak mass. This review is a consensus statement established by the national working group of the French Federation of CF Centers to develop practice guidelines for optimizing bone health in patients with CF. Recommendations for screening and for calcium, vitamin D and K supplementation are given. Further work is needed to define indications for treatment with biphosphonates and anabolic agents.
Subject(s)
Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/therapy , Cystic Fibrosis/complications , Osteoporosis/etiology , Adolescent , Bone Demineralization, Pathologic/epidemiology , Bone Density , Calcium/metabolism , Child , Child, Preschool , Exercise , Female , Humans , Intestinal Absorption , Male , Nutritional Status , Osteoporosis/epidemiology , Osteoporosis/therapy , Puberty , Vitamin D/therapeutic useABSTRACT
Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) is a branched-chain fatty acid derived from dietary sources and broken down in the peroxisome to pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) via alpha-oxidation. Pristanic acid then undergoes beta-oxidation in peroxisomes. Phytanic acid naturally occurs as a mixture of (3S,7R,11R)- and (3R,7R,11R)-diastereomers. In contrast to the alpha-oxidation system, peroxisomal beta-oxidation is stereospecific and only accepts (2S)-isomers. Therefore, a racemase called alpha-methylacyl-CoA racemase is required to convert (2R)-pristanic acid into its (2S)-isomer. To further investigate the stereochemistry of the peroxisomal oxidation systems and their substrates, we have developed a method using gas-liquid chromatography-mass spectrometry to analyze the isomers of phytanic, pristanic, and trimethylundecanoic acid in plasma from patients with various peroxisomal fatty acid oxidation defects. In this study, we show that in plasma of patients with a peroxisomal beta-oxidation deficiency, the relative amounts of the two diastereomers of pristanic acid are almost equal, whereas in patients with a defect of alpha-methylacyl-CoA racemase, (2R)-pristanic acid is the predominant isomer. Furthermore, we show that in alpha-methylacyl-CoA racemase deficiency, not only pristanic acid accumulates, but also one of the metabolites of pristanic acid, 2610-trimethylundecanoic acid, providing direct in vivo evidence for the requirement of this racemase for the complete degradation of pristanic acid.
Subject(s)
Fatty Acids/metabolism , Mixed Function Oxygenases/metabolism , Oxidoreductases/metabolism , Peroxisomal Disorders/metabolism , Phytanic Acid/metabolism , Racemases and Epimerases/metabolism , Fatty Acids/blood , Fatty Acids/chemistry , Humans , Mixed Function Oxygenases/deficiency , Oxidation-Reduction , Oxidoreductases/deficiency , Peroxisomal Disorders/blood , Peroxisomal Disorders/enzymology , Phytanic Acid/blood , Phytanic Acid/chemistry , Racemases and Epimerases/deficiency , Refsum Disease/blood , Refsum Disease/enzymology , Refsum Disease/metabolism , StereoisomerismABSTRACT
Peroxisomes play an indispensable role in cellular fatty acid oxidation in higher eukaryotes by catalyzing the chain shortening of a distinct set of fatty acids and fatty acid derivatives including pristanic acid (2,6,10,14-tetramethylpentadecanoic acid). Earlier studies have shown that pristanic acid undergoes three cycles of beta-oxidation in peroxisomes to produce 4,8-dimethylnonanoyl-CoA (DMN-CoA) which is then transported to the mitochondria for full oxidation to CO(2) and H(2)O. In principle, this can be done via two different mechanisms in which DMN-CoA is either converted into the corresponding carnitine ester or hydrolyzed to 4,8-dimethylnonanoic acid plus CoASH. The latter pathway can only be operational if peroxisomes contain 4,8-dimethylnonanoyl-CoA thioesterase activity. In this paper we show that rat liver peroxisomes indeed contain 4,8-dimethylnonanoyl-CoA thioesterase activity. We have partially purified the enzyme involved from peroxisomes and identified the protein as the rat ortholog of a known human thioesterase using MALDI-TOF mass spectrometry in combination with the rat EST database. Heterologous expression studies in Escherichia coli established that the enzyme hydrolyzes not only DMN-CoA but also other branched-chain acyl-CoAs as well as straight-chain acyl-CoA-esters. Our data provide convincing evidence for the existence of the second pathway of acyl-CoA transport from peroxisomes to mitochondria by hydrolysis of the CoA-ester in peroxisomes followed by transport of the free acid to mitochondria, reactivation to its CoA-ester, and oxidation to CO(2) and H(2)O. (c)2002 Elsevier Science.
Subject(s)
ATP-Binding Cassette Transporters , Escherichia coli Proteins , Liver/enzymology , Monosaccharide Transport Proteins , Peroxisomes/enzymology , Thiolester Hydrolases/genetics , Thiolester Hydrolases/metabolism , Animals , Carrier Proteins/genetics , Cloning, Molecular , Escherichia coli/chemistry , Escherichia coli/genetics , Expressed Sequence Tags , Fatty Acids/metabolism , Liver/chemistry , Male , Maltose-Binding Proteins , Mitochondria/metabolism , Molecular Sequence Data , Peroxisomes/chemistry , Rats , Rats, Wistar , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization , Subcellular Fractions/chemistry , Subcellular Fractions/enzymology , Thiolester Hydrolases/isolation & purificationABSTRACT
Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) is a branched-chain fatty acid which, due to the methyl-group at the 3-position, can not undergo beta-oxidation unless the terminal carboxyl-group is removed by alpha-oxidation. The structure of the phytanic acid alpha-oxidation machinery in terms of the reactions involved, has been resolved in recent years and includes a series of four reactions: (1) activation of phytanic acid to phytanoyl-CoA, (2) hydroxylation of phytanoyl-CoA to 2-hydroxyphytanoyl-CoA, (3) cleavage of 2-hydroxyphytanoyl-CoA to pristanal and formyl-CoA, and (4) oxidation of pristanal to pristanic acid. The subcellular localization of the enzymes involved has remained enigmatic, with the exception of phytanoyl-CoA hydroxylase and 2-hydroxyphytanoyl-CoA lyase which are both localized in peroxisomes. The oxidation of pristanal to pristanic acid has been claimed to be catalysed by the microsomal aldehyde dehydrogenase FALDH encoded by the ALDH10-gene. Making use of mutant fibroblasts deficient in FALDH activity, we show that phytanic acid alpha-oxidation is completely normal in these cells. Furthermore, we show that pristanal dehydrogenase activity is not fully deficient in FALDH-deficient cells, implying the existence of one or more additional aldehyde dehydrogenases reacting with pristanal. Using subcellular localization studies, we now show that peroxisomes contain pristanal dehydrogenase activity which leads us to conclude that the complete phytanic acid alpha-oxidation pathway is localized in peroxisomes.
Subject(s)
Aldehyde Oxidoreductases/metabolism , Aldehydes/metabolism , Fatty Acids/metabolism , Peroxisomes/metabolism , Phytanic Acid/metabolism , Aldehyde Oxidoreductases/deficiency , Animals , Fibroblasts/metabolism , Humans , In Vitro Techniques , Liver/metabolism , Male , Oxidation-Reduction , Peroxisomes/enzymology , Rats , Rats, Wistar , Refsum Disease/enzymology , Sjogren-Larsson Syndrome/genetics , Sjogren-Larsson Syndrome/metabolismABSTRACT
"French type" sialuria, a presumably dominant disorder that, until now, had been documented in only five patients, manifests with mildly coarse facies, slight motor delay, and urinary excretion of large quantities (>1 g/d) of free N-acetylneuraminic acid (NeuAc). The basic defect consists of the very rare occurrence of failed feedback inhibition of a rate-limiting enzyme, in this case uridinediphosphate-N-acetylglucosamine (UDP-GlcNAc) 2-epimerase, by a downstream product, in this case cytidine monophosphate (CMP)-NeuAc. We report a new patient with sialuria who has a heterozygous G-->A substitution in nucleotide 848 of the epimerase gene, which results in an R266Q change. The proband's other allele, as expected, had no mutation. However, the heterozygous R266Q mutation was detected in the patient's mother, who has similarly increased urinary levels of free NeuAc, thereby confirming, for the first time, the dominant mode of inheritance of this inborn error. The biochemical diagnosis of the proband was verified by the greatly increased level of free NeuAc in his cultured fibroblasts, the NeuAc distribution, mainly (59%) in the cytoplasm, and by the complete failure of 100 microM CMP-NeuAc to inhibit UDP-GlcNAc 2-epimerase activity in the mutant cells. These findings call for expansion of the phenotype to include adults and for more-extensive assaying of free NeuAc in the urine of children with mild developmental delay. The prevalence of sialuria is probably grossly underestimated.
Subject(s)
Carbohydrate Epimerases/genetics , Escherichia coli Proteins , Genes, Dominant/genetics , Metabolism, Inborn Errors/enzymology , Metabolism, Inborn Errors/genetics , Sialic Acids/urine , Adult , Base Sequence , Carbohydrate Epimerases/antagonists & inhibitors , Carbohydrate Epimerases/metabolism , Child , Child, Preschool , Cytidine Monophosphate N-Acetylneuraminic Acid/metabolism , Cytoplasm/metabolism , Developmental Disabilities/enzymology , Developmental Disabilities/genetics , Developmental Disabilities/physiopathology , Developmental Disabilities/urine , Feedback , Female , Fibroblasts , France , Heterozygote , Humans , Infant , Infant, Newborn , Male , Metabolism, Inborn Errors/physiopathology , Metabolism, Inborn Errors/urine , Middle Aged , Molecular Sequence Data , Mutation, Missense/genetics , Pedigree , Sialic Acids/analysis , Uridine Diphosphate N-Acetylglucosamine/metabolismABSTRACT
alpha-Methylacyl-CoA racemase plays an important role in the beta-oxidation of branched-chain fatty acids and fatty acid derivatives because it catalyzes the conversion of several (2R)-methyl-branched-chain fatty acyl-CoAs to their (S)-stereoisomers. Only stereoisomers with the 2-methyl group in the (S)-configuration can be degraded via beta-oxidation. Patients with a deficiency of alpha-methylacyl-CoA racemase accumulate in their plasma pristanic acid and the bile acid intermediates di- and trihydroxycholestanoic acid, which are all substrates of the peroxisomal beta-oxidation system. Subcellular fractionation experiments, however, revealed that both in humans and rats alpha-methylacyl-CoA racemase is bimodally distributed to both the peroxisome and the mitochondrion. Our findings show that the peroxisomal and mitochondrial enzymes are produced from the same gene and that, as a consequence, the bimodal distribution pattern must be the result of differential targeting of the same gene product. In addition, we investigated the physiological role of the enzyme in the mitochondrion. Both in vitro studies with purified heterologously expressed protein and in vivo studies in fibroblasts of patients with an alpha-methylacyl-CoA racemase deficiency revealed that the mitochondrial enzyme plays a crucial role in the mitochondrial beta-oxidation of the breakdown products of pristanic acid byconverting (2R,6)-dimethylheptanoyl-CoA to its (S)-stereoisomer.
Subject(s)
Liver/ultrastructure , Racemases and Epimerases/analysis , Racemases and Epimerases/physiology , Animals , Cell Fractionation , Fatty Acids/metabolism , Fibroblasts/enzymology , Humans , Liver/enzymology , Male , Mitochondria, Liver/enzymology , Mitochondria, Liver/physiology , Oxidation-Reduction , Peroxisomes/enzymology , Racemases and Epimerases/deficiency , Rats , Rats, WistarABSTRACT
Glucosidase I is an important enzyme in N-linked glycoprotein processing, removing specifically distal alpha-1,2-linked glucose from the Glc3Man9GlcNAc2 precursor after its en bloc transfer from dolichyl diphosphate to a nascent polypeptide chain in the endoplasmic reticulum. We have identified a glucosidase I defect in a neonate with severe generalized hypotonia and dysmorphic features. The clinical course was progressive and was characterized by the occurrence of hepatomegaly, hypoventilation, feeding problems, seizures, and fatal outcome at age 74 d. The accumulation of the tetrasaccharide Glc(alpha1-2)Glc(alpha1-3)Glc(alpha1-3)Man in the patient's urine indicated a glycosylation disorder. Enzymological studies on liver tissue and cultured skin fibroblasts revealed a severe glucosidase I deficiency. The residual activity was <3% of that of controls. Glucosidase I activities in cultured skin fibroblasts from both parents were found to be 50% of those of controls. Tissues from the patient subjected to SDS-PAGE followed by immunoblotting revealed strongly decreased amounts of glucosidase I protein in the homogenate of the liver, and a less-severe decrease in cultured skin fibroblasts. Molecular studies showed that the patient was a compound heterozygote for two missense mutations in the glucosidase I gene: (1) one allele harbored a G-->C transition at nucleotide (nt) 1587, resulting in the substitution of Arg at position 486 by Thr (R486T), and (2) on the other allele a T-->C transition at nt 2085 resulted in the substitution of Phe at position 652 by Leu (F652L). The mother was heterozygous for the G-->C transition, whereas the father was heterozygous for the T-->C transition. These base changes were not seen in 100 control DNA samples. A causal relationship between the alpha-glucosidase I deficiency and the disease is postulated.
Subject(s)
Carbohydrate Metabolism, Inborn Errors/enzymology , Carbohydrate Metabolism, Inborn Errors/genetics , Mutation, Missense/genetics , Oligosaccharides/metabolism , alpha-Glucosidases/deficiency , alpha-Glucosidases/genetics , Alleles , Blotting, Western , Brain/pathology , Carbohydrate Conformation , Carbohydrate Metabolism, Inborn Errors/complications , Carbohydrate Metabolism, Inborn Errors/urine , Carbohydrate Sequence , Chromatography, Thin Layer , Consanguinity , Fatal Outcome , Female , Fibroblasts , Glucose/analysis , Heterozygote , Humans , Infant , Infant, Newborn , Lactose/analysis , Liver/enzymology , Liver/pathology , Male , Molecular Sequence Data , Oligosaccharides/chemistry , Oligosaccharides/isolation & purification , Oligosaccharides/urine , alpha-Glucosidases/metabolismABSTRACT
Sterol carrier protein X (SCPx) plays a crucial role in the peroxisomal oxidation of branched-chain fatty acids. To investigate whether patients with an unresolved defect in peroxisomal beta-oxidation are deficient for SCPx, we developed a novel and specific assay to measure the activity of SCPx in both liver and fibroblast homogenates. The substrate used in the assay, 3alpha, 7alpha,12alpha-trihydroxy-24-keto-5beta-cholestanoy l-CoA (24-keto-THC-CoA), is produced by preincubating the enoyl-CoA of the bile acid intermediate THCA with a lysate from the yeast Saccharomyces cerevisiae expressing human D-bifunctional protein. After the preincubation period, liver or fibroblast homogenate is added plus CoASH, and the production of choloyl-CoA is determined by HPLC. The specificity of the assay was demonstrated by the finding of a full deficiency in fibroblasts from an SCPx knock-out mouse. In addition to SCPx activity measurements in fibroblasts from patients with a defect in peroxisomal beta-oxidation of unresolved etiology, we studied the stability and activity of SCPx in fibroblasts from patients with Zellweger syndrome, which lack functional peroxisomes. We found that SCPx is not only stable in the cytosol, but displays a higher activity in fibroblasts from patients with Zellweger syndrome than in control fibroblasts. Furthermore, in all patients studied with a defect in peroxisomal beta-oxidation of unknown origin, SCPx was found to be normally active, indicating that human SCPx deficiency remains to be identified.
Subject(s)
Acetyl-CoA C-Acetyltransferase/metabolism , Carrier Proteins/metabolism , Fatty Acids/metabolism , Liver/metabolism , Peroxisomes/metabolism , Zellweger Syndrome/metabolism , Animals , Cell Line , Fibroblasts/enzymology , Fibroblasts/metabolism , Humans , Liver/enzymology , Oxidation-Reduction , Peroxisomes/enzymology , Rats , Sensitivity and SpecificityABSTRACT
To study the putative role of human carnitine octanoyltransferase (COT) in the beta-oxidation of branched-chain fatty acids, we identified and cloned the cDNA encoding human COT and expressed it in the yeast Saccharomyces cerevisiae. Enzyme activity measurements showed that COT efficiently converts one of the end products of the peroxisomal beta-oxidation of pristanic acid, 4, 8-dimethylnonanoyl-CoA, to its corresponding carnitine ester. Production of the carnitine ester of this branched/medium-chain acyl-CoA within the peroxisome is required for its transport to the mitochondrion where further beta-oxidation occurs. In contrast, 4, 8-dimethylnonanoyl-CoA is not a substrate for carnitine acetyltransferase, another acyltransferase localized in peroxisomes, which catalyzes the formation of carnitine esters of the other products of pristanic acid beta-oxidation, namely acetyl-CoA and propionyl-CoA. Our results shed new light on the function of COT in fatty acid metabolism and point to a crucial role of COT in the beta-oxidation of branched-chain fatty acids.
Subject(s)
Carnitine Acyltransferases/genetics , Carnitine Acyltransferases/metabolism , Fatty Acids/metabolism , Amino Acid Sequence , Animals , Base Sequence , Cattle , Cloning, Molecular , DNA Primers/genetics , DNA, Complementary/genetics , Gene Expression , Humans , In Vitro Techniques , Microbodies/metabolism , Molecular Sequence Data , Oxidation-Reduction , Rats , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Saccharomyces cerevisiae/genetics , Sequence Homology, Amino Acid , Species SpecificityABSTRACT
Oxidation of straight-chain fatty acids in mitochondria involves the complicated interaction between a large variety of different enzymes. So far four different mitochondrial straight-chain acyl-CoA dehydrogenases have been identified. The physiological function of three of the four acyl-CoA dehydrogenases has been resolved in recent years especially from studies on patients suffering from certain inborn errors of mitochondrial fatty acid beta-oxidation. The physiological role of long-chain acyl-CoA dehydrogenase (LCAD) has remained obscure, however. The results described in this paper provide strong evidence suggesting that LCAD plays a central role in branched-chain fatty acid metabolism since it turns out to be the major acyl-CoA dehydrogenase reacting with 2,6-dimethylheptanoyl-CoA, a metabolite of pristanic acid, which itself is the alpha-oxidation product of phytanic acid.
Subject(s)
Acyl-CoA Dehydrogenase, Long-Chain/metabolism , Coenzyme A/metabolism , Fatty Acids/metabolism , Oxidoreductases Acting on CH-CH Group Donors , Acyl-CoA Dehydrogenase, Long-Chain/deficiency , Cells, Cultured , Humans , Mitochondria/metabolism , Oxidation-Reduction , Oxidoreductases/metabolism , Substrate SpecificitySubject(s)
Oxidoreductases Acting on CH-CH Group Donors , Oxidoreductases/metabolism , Smith-Lemli-Opitz Syndrome/diagnosis , Smith-Lemli-Opitz Syndrome/enzymology , Cell Line , Cells, Cultured , Chorionic Villi/enzymology , Dehydrocholesterols/metabolism , Fibroblasts/enzymology , Humans , Infant, Newborn , Male , Skin/cytology , Skin/enzymologyABSTRACT
Two methods are described, both currently used in our laboratory, for the quantitative analysis of very long-chain fatty acids, phytanic acid and pristanic acid in plasma and cultured fibroblasts by gas-liquid chromatography. The first method is based on the procedure developed by Moser and Moser (1991) and the second is based on the method of Onkenhout and colleagues (1989), which is an application of the original method of Lepage and Roy for plasma and fibroblasts. A survey is given of the concentrations of very long-chain fatty acids, pristanic and phytanic acid in plasma and fibroblasts from control subjects and all patients investigated so far in our laboratory.
Subject(s)
Fatty Acids/analysis , Phytanic Acid/analysis , Adrenoleukodystrophy/blood , Adrenoleukodystrophy/diagnosis , Adrenoleukodystrophy/metabolism , Cells, Cultured , Chromatography, Gas , Esters/analysis , Esters/chemical synthesis , Fatty Acids/blood , Fibroblasts/chemistry , Fibroblasts/metabolism , Humans , Indicators and Reagents , Phytanic Acid/blood , Solutions , SolventsABSTRACT
The direct transesterification method of Lepage and Roy is described as used in our laboratory for the analysis of plasmalogens and polyunsaturated fatty acids in erythrocytes and cultured fibroblasts by gas chromatography. An overview is given of the plasmalogen ratios and docosahexaenoic acid concentrations from controls and patients with different peroxisomal disorders investigated in our laboratory.
Subject(s)
Erythrocytes/chemistry , Fatty Acids, Unsaturated/analysis , Plasmalogens/analysis , Adolescent , Child , Chromatography, Gas , Docosahexaenoic Acids/analysis , Docosahexaenoic Acids/blood , Fatty Acids, Unsaturated/blood , Fibroblasts/chemistry , Humans , Peroxisomal Disorders/blood , Peroxisomal Disorders/metabolism , Plasmalogens/blood , SolventsABSTRACT
Prolonged treatment of cultured cells with ethidium bromide results in loss of the capacity for oxidative phosphorylation. Because of the tight coupling between mitochondrial beta-oxidation of fatty acids and the activity of the respiratory chain, such cells may be used to study the contribution of mitochondria and peroxisomes to fatty acid beta-oxidation. To investigate this, human skin fibroblasts were cultured in the presence of ethidium bromide for at least 10 cell generations, resulting in a virtually complete absence of oxidative phosphorylation as demonstrated directly in digitonin-permeabilized fibroblasts. The cells showed a lowered ATP/ADP ratio, most likely as the consequence of the inability to generate ATP via oxidative phosphorylation. The loss of the capacity for oxidative phosphorylation was also reflected in an increased cytosolic NADH/NAD+ ratio: the cells showed a highly elevated lactate/pyruvate ratio in the suspending medium when incubated with glucose. The beta-oxidation of octanoic and palmitic acid was dramatically decreased, suggesting that the beta-oxidation of these fatty acids takes place predominantly (> 90%) in mitochondria, at least in the cells studied. In contrast, the rates of pristanic and cerotic acid beta-oxidation were only slightly decreased, suggesting that this is mainly a peroxisomal process. The reduction of beta-oxidation of cerotic and pristanic acid, 27% and 15%, respectively, is most likely due to a lowered ATP level and an increased NADH/NAD(+)-redoxstate in these cells. We conclude that fibroblasts subjected to prolonged treatment with ethidium bromide can be used as a model system to study the substrate specificity and functional characteristics of the peroxisomal beta-oxidation system.
Subject(s)
Fatty Acids/metabolism , Oxidative Phosphorylation , Skin/metabolism , Caprylates/metabolism , Cells, Cultured , DNA/analysis , Ethidium , Fibroblasts/metabolism , Humans , Microbodies/enzymology , Mitochondria/enzymology , Mitochondria/metabolism , Models, Biological , Palmitic Acid , Palmitic Acids/metabolismABSTRACT
C 26:0/C 22:0 ratio can be experimentally increased in serum of normal rats by oral administration of hexacosanoic acid (C 26:0) or of thioridazine, an inhibitor of peroxisomal beta-oxidation. This causes a decreased corticosterone response as well as decreased mobilization of cholesterol esters in zona fasciculata interna cells following ACTH administration. Zona fasciculata interna cells and their nuclei are enlarged and contain more Feulgen DNA in thioridazine-fed rats. The similarity of adrenocortical response to inhibition of peroxisomal beta-oxidation and to C 26:0 administration points to raised VLCFA as the common factor which is also operative in many peroxisomal diseases accompanied by adrenocortical function defects.
Subject(s)
Adrenocorticotropic Hormone/drug effects , Corticosterone/blood , Fatty Acids/blood , Thioridazine/administration & dosage , Adrenal Glands/anatomy & histology , Adrenal Glands/drug effects , Animals , Body Weight/drug effects , Fatty Acids/administration & dosage , Male , Rats , Rats, Wistar , Zona Fasciculata/cytology , Zona Fasciculata/drug effectsABSTRACT
We have studied the substrate specificity of the inducible (acyl-CoA oxidase I) and non-inducible (acyl-CoA oxidase II) oxidases in peroxisome-enriched fractions from rat kidney. The two oxidases were separated by means of ion-exchange chromatography and shown to accept a variety of acyl-CoA esters as substrates, including lignoceroyl-CoA, palmitoyl-CoA, lauroyl-CoA, caproyl-CoA, and trimethyltridecanoyl-CoA. Glutaryl-CoA was found to react exclusively with the inducible enzyme, and pristanoyl-CoA exclusively with the non-inducible enzyme. We conclude that under normal non-induced conditions both acyl-CoA oxidase I and II contribute to the oxidation of the various acyl-CoA esters with the exception of pristanoyl-CoA and glutaryl-CoA, although the extent to which each enzyme contributes to the oxidation was found to differ between the various acyl-CoA esters.
Subject(s)
Acyl Coenzyme A/metabolism , Kidney/enzymology , Microbodies/enzymology , Oxidoreductases/metabolism , Acyl-CoA Oxidase , Animals , Cell Fractionation , Chromatography, Ion Exchange , Enzyme Induction , Esters , Oxidation-Reduction , Oxidoreductases/isolation & purification , Rats , Substrate SpecificityABSTRACT
Isoprenoid (branched) fatty acids such as pristanic acid can be degraded via beta-oxidation in peroxisomes. We synthesized 2-methylpalmitoyl-CoA as a model substrate in order to study the first step of the peroxisomal beta-oxidation of branched fatty acids, catalyzed by an acyl-CoA oxidase. 2-Methylpalmitoyl-CoA oxidase activity was found in rat liver homogenates. Subcellular fractionation demonstrated that the oxidase was confined to peroxisomes. 2-Methylpalmitoyl-CoA oxidase was also present in kidney and intestine. It was not induced in liver or in the extrahepatic tissues by treatment of rats with peroxisome proliferators or by feeding diets containing excess isoprenoids. The enzyme was partially purified together with palmitoyl-CoA oxidase and trihydroxycoprostanoyl-CoA oxidase by heat treatment and ammonium sulfate fractionation of liver extracts. The partially purified preparation was chromatographed on various columns. 2-Methylpalmitoyl-CoA oxidase could be separated from the inducible (by peroxisome proliferators) palmitoyl-CoA oxidase and from trihydroxycoprostanoyl-CoA oxidase, but it always coeluted with the noninducible palmitoyl-CoA oxidase, recently described by us (Schepers, L., Van Veldhoven, P. P., Casteels, M., Eyssen, H. J., and Mannaerts, G. P. (1990) J. Biol. Chem. 265, 5242-5246). 2-Methylpalmitoyl-CoA oxidase was purified to near homogeneity in three chromatographic steps (anion exchange, hydroxylapatite, and gel filtration). Its apparent molecular mass is approximately 415 kDa, and it consists of identical subunits of approximately 70 kDa. The enzyme oxidized 2-methylpalmitoyl-CoA twice as rapidly as palmitoyl-CoA and pristanoyl-CoA as rapidly as palmitoyl-CoA, so that it can be considered as a branched fatty acyl-CoA oxidase. Since pristanoyl-CoA is one of its naturally occurring substrates we propose to name this enzyme pristanoyl-CoA oxidase.
Subject(s)
Liver/enzymology , Microbodies/enzymology , Oxidoreductases/isolation & purification , Animals , Chromatography, Liquid , Electrophoresis, Polyacrylamide Gel , Fenofibrate/pharmacology , Hot Temperature , Liver/metabolism , Male , Microbodies/drug effects , Microbodies/metabolism , Oxidation-Reduction , Oxidoreductases/metabolism , Palmitic Acids/metabolism , Rats , Rats, Inbred StrainsABSTRACT
A case of X-linked recessive chondrodysplasia punctata (CP) is described. The finding of a reciprocal X-Y translocation involving the region distal to Xp22.3 and the presence of fluorescent Yp11.23 regions confirms the localization of X-linked recessive CP at p22.3. No gross peroxisomal abnormalities were present in the propositus.
Subject(s)
Chondrodysplasia Punctata/genetics , Genes, Recessive , Genetic Linkage , Translocation, Genetic , X Chromosome , Y Chromosome , Adult , DNA/analysis , Female , Fetal Death , Humans , Immunohistochemistry , Karyotyping , Male , Microbodies/ultrastructureABSTRACT
Five brain-derived and 17 urinary oligomannose-type oligosaccharides were isolated by ion-exchange chromatography on Mono Q or Dowex, followed by HPLC on Lichrosorb-NH2 from a Persian cat suffering from alpha-mannosidosis. The structures of the carbohydrate chains were determined by 500- or 600-MHz 1H-NMR spectroscopy. Different oligosaccharide patterns were found in brain and urine. 99% of the urinary oligosaccharides possess an alpha(1-6)-linked mannose residue attached to beta-mannose, whereas only 5% of the brain-derived oligosaccharides contain such a residue. Furthermore, of the urinary carbohydrate chains 71% end with Man beta 1-4GlcNAc beta 1-4GlcNAc and 29% end with Man beta 1-4GlcNAc, whereas the corresponding amounts are 23% and 77%, respectively, for the brain-derived oligosaccharides.
Subject(s)
Brain/metabolism , Oligosaccharides/chemistry , alpha-Mannosidosis/metabolism , Animals , Carbohydrate Sequence , Cats , Chemical Fractionation , Chromatography, High Pressure Liquid , Magnetic Resonance Spectroscopy , Molecular Sequence Data , Oligosaccharides/metabolism , Oligosaccharides/urine , Protons , alpha-Mannosidosis/urineABSTRACT
A boy born to healthy, unrelated parents, presented at birth with hypotonia and seizures. Very long chain fatty acids in the plasma were strongly elevated; bile acid intermediates and plasmalogen biosynthesis were normal. Acyl-CoA oxidase activity was normal. The patient died at the age of 3 months. The cerebellum and medulla oblongata showed neuronal migration defects. The specific biochemical basis for the impaired peroxisomal beta-oxidation has not been found. The three immunoreactive peroxisomal beta-oxidation enzymes and catalase were localized in the hepatocellular peroxisomes. Aberrant features of the peroxisomes included: a subpopulation of organelles larger than 1 micron, an amorphous nucleoid in many organelles, and invaginations of the peroxisomal membrane into the matrix. Peroxisomes in the proximal renal tubules also contained the three immunoreactive beta-oxidation enzymes. Regularly spaced trilamellar inclusions were seen in hepatic macrophages; they were much more abundant in adrenocortical macrophages. The inclusions were birefringent and resistant to acetone extraction. Distinct hepatic fibrosis had developed over a period of 2.5 months. We speculate that the impaired beta-oxidation is due to a defect at the level of the peroxisomal carnitine octanoyl or -acetyl transferase, responsible for the export of beta-oxidation products.